Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta Genasense Fails To Demonstrate “Any Clinical Benefit” Improvements, FDA Tells Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

Latest supplement to support a venous thromboembolism indication for Pfizer’s Fragmin will also be discussed by Oncologic Drugs Advisory Committee Sept. 6.

You may also be interested in...



Genta CLL Agent Genasense Has Not Shown Clinical Benefit, FDA Panel Says

Committee votes seven to three that data from Genta’s randomized trial of the chronic lymphocytic leukemia therapy does not represent substantial evidence of clinical benefit during Sept. 6 meeting.

Pfizer’s Antithrombotic Fragmin Recommended For Use In Cancer Patients

FDA's Oncologic Drugs Advisory Committee unanimously recommended approval of an sNDA for Pfizer's low molecular weight heparin Fragmin for treatment and prevention of venous thromboembolism in cancer patients

Genta CLL Agent Genasense Has Not Shown Clinical Benefit, FDA Panel Says

Committee votes seven to three that data from Genta’s randomized trial of the chronic lymphocytic leukemia therapy does not represent substantial evidence of clinical benefit during Sept. 6 meeting.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel